Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MARX Biotech CoROCO:7731 -2.18%8 Buyback Yield % is -2.49 as of Jul. 27, 2026. GuruFocus rates ROCO:7731 with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 276 Healthcare Providers & Services companies, MARX Biotech Co ranks worse than 67.03% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for MARX Biotech Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MARX Biotech Co Buyback Yield % Competitor Comparison
For the Pharmaceutical Retailers subindustry, MARX Biotech Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MARX Biotech Co Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where MARX Biotech Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MARX Biotech Co (ROCO:7731) has a Buyback Yield % of -2.49 as of Jul. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MARX Biotech Co and its competitors. According to the industry distribution chart, MARX Biotech Co ranks #185 out of 276 companies in the Healthcare Providers & Services industry, placing it in the top 67%.
Is MARX Biotech Co's Buyback Yield % too high?
MARX Biotech Co's current Buyback Yield % is -2.49. Based on the distribution chart, MARX Biotech Co ranks #185 out of 276 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MARX Biotech Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's Buyback Yield % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, MARX Biotech Co ranks #185 out of 276 companies for Buyback Yield %. This places MARX Biotech Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MARX Biotech Co and its competitors. MARX Biotech Co's current Buyback Yield % is -2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current Buyback Yield % of -2.49. The current Buyback Yield % is -2.49. MARX Biotech Co's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current Buyback Yield % is -2.49 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
8GF Score
Get the complete analysis for ROCO:7731
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7731 has been successfully added to your 
